Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
Edwards Lifesciences looks ahead | FDA chief's vaccine claims | Pope Leo meets with cardiologists | TAVR & vulnerable patients
Monday, December 8, 2025
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

Edwards Lifesciences shares positive outlook for 2026, pointing to continued importance of TAVR

The company expects TAVR sales alone to be as high as $4.9 billion in 2026. Other minimally invasive therapies are projected to make a major impact as well.

READ MORE >
Edwards Lifesciences Sapien 3 TAVR valves at TCT 2024 DF 1
Share on Twitter Share on Facebook Share on Linkedin

Edwards Lifesciences shares positive outlook for 2026, pointing to continued importance of TAVR

Share on Twitter Share on Facebook Share on Linkedin
Edwards Lifesciences Sapien 3 TAVR valves at TCT 2024 DF 1
The company expects TAVR sales alone to be as high as $4.9 billion in 2026. Other minimally invasive therapies are projected to make a major impact as well.
READ MORE >

FDA commissioner claims Biden administration hid heart risks of COVID-19 vaccines from public

The allegation came days after an internal FDA memo linked the vaccines to the deaths of multiple children. A group of former FDA commissioners pushed back against the content of that memo.

READ MORE >
artificial intelligence ai in healthcare
Share on Twitter Share on Facebook Share on Linkedin

FDA commissioner claims Biden administration hid heart risks of COVID-19 vaccines from public

Share on Twitter Share on Facebook Share on Linkedin
artificial intelligence ai in healthcare
The allegation came days after an internal FDA memo linked the vaccines to the deaths of multiple children. A group of former FDA commissioners pushed back against the content of that memo.
READ MORE >

Pope welcomes cardiologists to Vatican City

Pope Leo XIV told interventional cardiologists their work “stands at the crossroads of science, compassion and ethical responsibility.” When they treat patients, he added, they are treating the heart “both physically and metaphorically, bringing relief to those who suffer.” 

READ MORE >
Pope Leo XIV interventional cardiology
Share on Twitter Share on Facebook Share on Linkedin

Pope welcomes cardiologists to Vatican City

Share on Twitter Share on Facebook Share on Linkedin
Pope Leo XIV interventional cardiology
Pope Leo XIV told interventional cardiologists their work “stands at the crossroads of science, compassion and ethical responsibility.” When they treat patients, he added, they are treating the heart “both physically and metaphorically, bringing relief to those who suffer.” 
READ MORE >

TAVR still a safe treatment option for immunocompromised patients

While patients with a weakened immune system are still more likely to die after TAVR than other patients, those deaths are largely not related to the procedure or any other cardiovascular issues. This new meta-analysis explored data from a variety of clinical trials.

READ MORE >
Doctor patient
Share on Twitter Share on Facebook Share on Linkedin

TAVR still a safe treatment option for immunocompromised patients

Share on Twitter Share on Facebook Share on Linkedin
Doctor patient
While patients with a weakened immune system are still more likely to die after TAVR than other patients, those deaths are largely not related to the procedure or any other cardiovascular issues. This new meta-analysis explored data from a variety of clinical trials.
READ MORE >

Featured Articles

FDA panel votes against approving first-of-its-kind heart failure device

All 15 members of the FDA's Circulatory System Devices Panel agreed that more data is required to confirm the new device from Johnson & Johnson MedTech is effective. Will the agency agree with these recommendations? Only time will tell.

READ MORE >
V-Wave has gained considerable attention or its Ventura Interatrial Shunt System, a small implantable device designed to reduce pressure on the left atrium and the lungs in patients with heart failure with reduced ejection fraction (HFrEF). The Ventura device includes a nitinol hourglass-shaped frame that anchors to the patient’s fossa ovalis in a way that prevents migration or embolization. It is implanted via an interventional procedure with fluoroscopy and echocardiography guidance.
Share on Twitter Share on Facebook Share on Linkedin

FDA panel votes against approving first-of-its-kind heart failure device

Share on Twitter Share on Facebook Share on Linkedin
V-Wave has gained considerable attention or its Ventura Interatrial Shunt System, a small implantable device designed to reduce pressure on the left atrium and the lungs in patients with heart failure with reduced ejection fraction (HFrEF). The Ventura device includes a nitinol hourglass-shaped frame that anchors to the patient’s fossa ovalis in a way that prevents migration or embolization. It is implanted via an interventional procedure with fluoroscopy and echocardiography guidance.
All 15 members of the FDA's Circulatory System Devices Panel agreed that more data is required to confirm the new device from Johnson & Johnson MedTech is effective. Will the agency agree with these recommendations? Only time will tell.
READ MORE >

FDA clears new left-heart access system from Atraverse Medical

The Hotwire Transseptal Access System includes the Hotwire RF Generator and Hotwire RF Guidewire, giving electrophysiologists the tools they need for left-heart access. 

READ MORE >
Hotwire Transseptal Access System Atraverse Medical
Share on Twitter Share on Facebook Share on Linkedin

FDA clears new left-heart access system from Atraverse Medical

Share on Twitter Share on Facebook Share on Linkedin
Hotwire Transseptal Access System Atraverse Medical
The Hotwire Transseptal Access System includes the Hotwire RF Generator and Hotwire RF Guidewire, giving electrophysiologists the tools they need for left-heart access. 
READ MORE >

Medtronic launches new diabetes tech integrated with Abbott sensor

Two of the world's leading healthcare companies have partnered on a new treatment option for patients with type 1 diabetes.

READ MORE >
MiniMed 780G system integrated with Instinct sensors manufactured by Abbott.
Share on Twitter Share on Facebook Share on Linkedin

Medtronic launches new diabetes tech integrated with Abbott sensor

Share on Twitter Share on Facebook Share on Linkedin
MiniMed 780G system integrated with Instinct sensors manufactured by Abbott.
Two of the world's leading healthcare companies have partnered on a new treatment option for patients with type 1 diabetes.
READ MORE >

In Case You Missed It

SCAI: Noncompete contracts unfairly bind cardiologists to hospitals unless they move

"These provisions are contained in what amounts, in many cases, to contracts of adhesion, because a physician’s only choice is to accept the terms of the contract without revision or else forgo employment," the Society for Cardiovascular Angiography and Interventions wrote to the U.S. Federal Trade Commission.

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

SCAI: Noncompete contracts unfairly bind cardiologists to hospitals unless they move

Share on Twitter Share on Facebook Share on Linkedin
"These provisions are contained in what amounts, in many cases, to contracts of adhesion, because a physician’s only choice is to accept the terms of the contract without revision or else forgo employment," the Society for Cardiovascular Angiography and Interventions wrote to the U.S. Federal Trade Commission.
READ MORE >

Myval TAVR valve outperforms Sapien and Evolut in the late-breaking LANDMARK trial

The LANDMARK trial continues to show positive outcomes for the TAVR valve made in India.

READ MORE >
Meril Life Sciences, an India-based medical device company founded in 2006, developed the Myval TAVR valve. The Myval transcatheter heart valve (THV) is non-inferior to the Sapien 3 THV after one year, according to new transcatheter aortic valve replacement (TAVR) data published in The Lancet.
Share on Twitter Share on Facebook Share on Linkedin

Myval TAVR valve outperforms Sapien and Evolut in the late-breaking LANDMARK trial

Share on Twitter Share on Facebook Share on Linkedin
Meril Life Sciences, an India-based medical device company founded in 2006, developed the Myval TAVR valve. The Myval transcatheter heart valve (THV) is non-inferior to the Sapien 3 THV after one year, according to new transcatheter aortic valve replacement (TAVR) data published in The Lancet.
The LANDMARK trial continues to show positive outcomes for the TAVR valve made in India.
READ MORE >

Device to treat coronary microvascular disease rakes in $23 million in financing

With no treatments available that directly improve INOCA, this breakthrough device offers hope.

READ MORE >
VahatiCor's investigational A-Flux Reducer System helps increase perfusion by restricting the venous flow in the coronary sinus.
Share on Twitter Share on Facebook Share on Linkedin

Device to treat coronary microvascular disease rakes in $23 million in financing

Share on Twitter Share on Facebook Share on Linkedin
VahatiCor's investigational A-Flux Reducer System helps increase perfusion by restricting the venous flow in the coronary sinus.
With no treatments available that directly improve INOCA, this breakthrough device offers hope.
READ MORE >

In Other News

Kaiser Permanente agrees to $46M settlement over data incident affecting 13.4M people

The managed care company does not admit to doing anything wrong. The data breach constituted its use of third-party tracking technology on its website, which shared data with Google, Microsoft, Twitter, Meta and others.

READ MORE >
the-kaiser-permanente-thrive-center-street-telegraph_1300x867.jpg
Share on Twitter Share on Facebook Share on Linkedin

Kaiser Permanente agrees to $46M settlement over data incident affecting 13.4M people

Share on Twitter Share on Facebook Share on Linkedin
the-kaiser-permanente-thrive-center-street-telegraph_1300x867.jpg
The managed care company does not admit to doing anything wrong. The data breach constituted its use of third-party tracking technology on its website, which shared data with Google, Microsoft, Twitter, Meta and others.
READ MORE >

Radiology vendor Agfa to eliminate 145 positions amid continued declines in film business

The move is part of over $29 million (USD) in cost reductions, revealed last month during the Belgium-based company's quarterly earnings announcement. 

READ MORE >
Pascal Juéry CEO Agfa-Gevaert
Share on Twitter Share on Facebook Share on Linkedin

Radiology vendor Agfa to eliminate 145 positions amid continued declines in film business

Share on Twitter Share on Facebook Share on Linkedin
Pascal Juéry CEO Agfa-Gevaert
The move is part of over $29 million (USD) in cost reductions, revealed last month during the Belgium-based company's quarterly earnings announcement. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Medtech giant makes big move | The world’s top hospitals for heart surgery | New CPT codes | PET vs. SPECT | TAVR tech recalled
AI is gaining ground, but clinicians run the show | Siemens Healthineers doubles down | Electrophysiologist compensation
News Alert: FDA shares warning about heart valve tech after patient death
Cardiologist pay & productivity are up | FDA clears PE thrombectomy devices | Cardiology tech in spotlight | Gore's new approval
Cardiology salaries on the rise | The climbing costs of care | M&A trends | Siemens Healthineers, J&J make big business moves
Major MRI trends | Blood thinner recalled | When to perform PCI before TAVR | How to build a CCTA program | Steroids & the heart
CMS boosts coverage for heart failure tech | FDA approves CardioMEMS updates | LVADs linked to strokes, other risks
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme
Trimed Popup